The article argues that Medicare Administrative Contractors (MACs) — the regional insurers that process Medicare claims — exert a quiet but decisive influence over dermatology care across the United States, determining which drugs, devices and procedures reach patients even when the FDA has already cleared or approved them.

Who are the 'hidden bureaucrats'?

MACs are private companies contracted by the Centers for Medicare & Medicaid Services (CMS) to administer Medicare claims in defined jurisdictions across the country. Because dermatology practices operate within regional jurisdictions, the same drug or procedure can be covered in one part of the country and denied in another.

The article characterizes these contractors as "hidden bureaucrats": unelected, regionally fragmented decision-makers whose coverage documents directly shape clinical practice, often with less visibility than FDA action or CMS national policy.

What levers do MACs actually pull?

The piece centers on the instruments through which MACs constrain or enable dermatology care:

• Local Coverage Determinations (LCDs) — regional policies that define when a drug, device or procedure is "medically necessary."
• Coding and billing requirements — documentation thresholds that determine whether claims for dermatologic services are paid or denied.
• Coverage gaps by geography — divergent regional policies that produce unequal access to the same therapies.

For dermatologists, the practical consequence is straightforward: a practice's revenue and a patient's access can hinge on the wording of a regional policy rather than on clinical evidence or national standards of care.

Why does this matter for dermatology specifically?

Dermatology sits at the intersection of medical, surgical and aesthetic practice, making it unusually exposed to coverage ambiguity. Treatments that straddle categories — procedures with both therapeutic and cosmetic indications, biologics with restrictive step-therapy requirements, skin-cancer diagnostics with evolving evidence bases — are precisely the services where MAC discretion is greatest.

The article frames the problem as one of accountability and transparency: decisions that shape care for millions of Medicare beneficiaries are made contractor by contractor, jurisdiction by jurisdiction, without the public scrutiny that accompanies FDA approvals or national coverage determinations.

What can practices do?

The implied path forward for clinicians is engagement rather than passivity:

• Track LCDs and draft policies in their own MAC jurisdiction, since comment periods offer a window to influence policy before it takes effect.
• Align documentation with the specific medical-necessity language of their regional contractor.
• Anticipate divergence: evidence accepted in one jurisdiction may not satisfy the neighboring MAC.

As MAC policies continue to evolve alongside dermatology's expanding therapeutic arsenal, the practices that monitor their regional contractors' determinations will be the ones best positioned to protect both reimbursement and patient access.